Learn about: Overall Response Rate | Duration of Response

Overall Response Rate

JEMPERLI has demonstrated a clinically meaningful response1,2

  • Responses were consistent from the primary (n=71) through the updated (n=141) analyses
Icon: Overall Response Rate
Icon: Median follow-up of 27.6 months Updated Efficacy Analysis 45.4 % Overall Response Rate² ,95% CI (37.0, 54.0)
  • Response Rate Data

    12.7% of patients had a complete response and 29.6% of patients had a partial response in the primary analysis
    • Overall response rates based on lines of prior therapy2:
      • 42.9% (n=18) in those who received 1 prior line (95% CI [27.7, 59.0])
      • 41.4% (n=12) in those who received ≥2 prior lines (95% CI [23.5, 61.1])
      • Due to small sample sizes and wide confidence intervals, results should be interpreted with caution
    • Responses with JEMPERLI were seen across histologies, including serous, squamous, endometrioid, undifferentiated, and mixed carcinoma2
    15.6% of patients had a complete response and 29.8% of patients had a partial response in the primary analysis
    • Overall response rates based on lines of prior therapy2:
      • 43.8% (n=39) in those who received 1 prior line (95% CI [33.3, 54.7])
      • 48.1% (n=25) in those who received ≥2 prior lines (95% CI [34.0, 62.4])
      • Due to small sample sizes and wide confidence intervals, results should be interpreted with caution
    • Responses with JEMPERLI were seen across histologies, including serous, squamous, endometrioid, undifferentiated, and mixed carcinoma2

NCCN recommends dostarlimab-gxly (JEMPERLI) in patients with dMMR recurrent or advanced endometrial carcinoma that has progressed on or following prior treatment with a platinum-containing regimen3

Icon: Lightbulb

Duration of Response

JEMPERLI has shown durable response over follow-up1,2,4

In both the primary (n=71) and updated analyses (n=141), median duration of response was not reached

  • Primary: 93.3% of responding patients demonstrated a duration of response ≥6 months (median follow-up of 14.1 months)*
  • Updated: 79.7% of responding patients demonstrated a duration of response ≥1 year (median follow-up of 27.6 months)

*

Measured from time of first response.

Graph displaying duration of response in responders in the primary analysis

These responses are based on a median duration of follow-up of 11.2 months.

  • Estimated Duration of Response

    Estimated probability of patients remaining in response at 2 years2

    Probability of response estimated from Kaplan-Meier curve with a median follow-up of 27.6 months

    Estimated duration of response per RECIST v1.1, based on BICR assessment2

    Graph displaying estimated probability of patients remaining in response at 2 years

    Median duration of response (DOR) had still not been reached at 27.6 months median follow-up2

    Icon: Lightbulb
Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial
for JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Safety

Learn about the safety profile
and tolerability of JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.